Sector News

Stada CEO ‘happy’ to take 40% pension cut. Sound foreign, U.S. pharma chiefs?

November 14, 2014
Life sciences
Here’s something you don’t see in the U.S.: The chief exec of Germany’s largest independent pharma has agreed to a pension cut worth about 40%–a change he says he was “happy” to consent to.
 
Stada CEO Hartmut Retzlaff’s retirement package will get a €16 slim-down to about €24 million ($29.9 million), Reuters reports. Retzlaff waived the money before taxes as part of a transfer of the package from Stada to an external pension fund, which had been “planned for a long time,” the company’s CFO said on a conference call Thursday.
 
The package for the 21-year helmsman is a far cry from the kind of money long-tenured pharma CEOs can take home in the States. For comparison, former Johnson & Johnson chief Bill Weldon took home a $143 million package when he retired in 2012 after a 40-year stint at the New Jersey drugmaker, with 10 of those years spent in the CEO’s chair.
 
But in Europe, citizens have been known to raise fury over large retirement packages. Just ask former Novartis skipper Daniel Vasella, who saw his 72-million-franc ($74.4 million) goodbye present whittled down to $5.2 million after protests from pay watchdogs. (Swiss voters later passed a referendum giving shareholders the right to reject pay packages for top managers).
 
So while Retzlaff said on the call that he “was happy to” agree to the change in plan–which he didn’t have to do, he noted–he also made the case for the sum he’s still due after retirement.
 
“We managed under my leadership to turn this company, which at the time was already almost a hundred years old, from little better than a rabbit hutch into a reputable MDAX company,” he said, as quoted by Reuters.
 
By Carly Helfand
 

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach